Specific Clostridium bacteria in the gut cause MS symptoms through an “epsilon toxin” that triggers “Myelin-itis.” The twin-based and animal study is so robust that we must take it very seriously. Perhaps this holds the key to understanding primary progressive MS?
Prologue
Just now, a patient came in with symptoms of what is named by neurologists as as a “spastic sensorimotor polyneuropathy” (that is: paralysis of the lower-leg muscles with numbness of the feet and lower legs).
Petros, who has seen this patient about a year ago ment that this would be definitly a hereditary sensorimotor PNP but the genetic tests failed. The patient visited us last fall to start her neuromodulation and came now back for a control date.
The spastic component had improved dramatically after several months of home-treatment neuromodulation. The sensorimotor polyneuropathy as well had clearly improved and still is improved, actually, I can hardly notice anything when she walks though she claims a strong relaps of the disease:
shortly before Christmas, she developed microscopic colitis, needing cortison and since then she claims all peripheral symptoms have worsened again.
Background history: since the age of 16, alternating phases of severe diarrhea and constipation.
In this context, I could not help but think of a very recent tweet that had deeply impressed me:
This topic is so meaningful as a potential trigger of neurological disease (my newest area of focus) that it clearly warrants deeper investigation.
Gut microbiome and multiple sclerosis
What the new data really show – and what is still speculation
Over the past weeks, this widely discussed X.com thread by Craig Brockie has attracted considerable attention. It summarizes new findings on the role of the gut microbiome in the development of MS-typical lesions.
Below is a calm, evidence-based assessment, without sensationalism.
Specific bacteria trigger multiple sclerosis in twin studies
Several research groups have been investigating for years whether specific bacterial patterns in the gut can influence autoimmune processes in the central nervous system.
The study discussed in the thread (popular science summary, among others on earth.com) essentially reports the following:
- In identical twin pairs where only one twin developed MS, the affected twin showed higher levels of certain anaerobic gut bacteria, particularly Eisenbergiella tayi and Lachnoclostridium.
- These bacteria preferentially colonize the terminal ileum, a region with high immunological activity.
- Transfer of the gut microbiota from MS patients to mice led, in a significant proportion of animals, to the development within weeks of inflammatory spinal cord lesions that resemble MS plaques. Control animals (microbiome from healthy twins) did not develop these changes.
- Functionally relevant is the fact that, under conditions of low dietary fiber intake, these bacteria increasingly degrade mucus. This weakens the intestinal barrier and facilitates contact between bacterial metabolites and the immune system.
- Discussed metabolites include succinate and ethanol, which can amplify pro-inflammatory T-cell responses, including those targeting myelin.
- In the mouse model, the effect was more pronounced in females, which aligns epidemiologically with the higher prevalence of MS in women.
These findings fit well with earlier work showing that transfer of an MS-associated microbiome enhances autoimmunity in animal models (e.g., Berer et al., PNAS).
Assessment of the evidence
It is important to clearly separate findings from interpretation:
- The data are strong at the preclinical level, because twin study designs were combined with functional mouse models.
- A definitive clinical causality in humans is not yet proven.
- This is not about acute paralysis caused by a single neurotoxin, but about chronic immune dysregulation leading to inflammatory demyelinating lesions.
On the question of “Botox-like” toxins
A natural question arises:
If these are (at least in part) Clostridia-related bacteria, could neurotoxic substances play a role, similar to botulism?
Here, precision is essential:
- Botulinum toxin is a highly potent, specific neurotoxin that blocks acetylcholine release at the neuromuscular junction, causing flaccid paralysis. This clinical picture does not match MS, either clinically or pathophysiologically.
- However, there are other clostridial toxins with neuroinflammatory potential. Particularly relevant is the epsilon toxin of Clostridium perfringens:
- In animal models, this toxin can cross the blood–brain barrier.
- It shows affinity for myelin-rich regions.
- In experimental models, it can induce or exacerbate demyelinating lesions.
- Crucially, this is not a direct “Botox-like” blockade of nerve conduction, but rather damage to and activation of immunological and glial processes, which secondarily lead to myelin loss –> which is exactly what happens in MS.
For Eisenbergiella tayi and Lachnoclostridium themselves, there is currently no solid evidence that they produce classical neurotoxins.
The more likely mechanism is:
- Disruption of the intestinal barrier
- Immune-activating metabolites
- Misdirected T-cell responses
- Secondary inflammation within the CNS
In short:
The process is immuno-inflammatory, not toxic-paralytic.
Therapeutic implications (carefully stated)
From the available data, no simple therapeutic promises can be derived, but plausible approaches emerge:
- High-fiber nutrition to prevent mucus degradation.
- Targeted microbiome modulation instead of broad immunosuppression.
- Looking ahead:
- Selective antibiotics
- Bacteriophages
- Defined probiotics
- These strategies remain experimental and do not belong in routine MS therapy at present, but clearly do belong in research.
Conclusion
Current studies support the concept that specific gut bacteria, in the presence of genetic susceptibility, may act as triggers or amplifiers of autoimmune processes.
MS thus appears even more clearly as a systemic disorder of the gut–immune–brain axis – not as a classic infection, and not as a toxin-mediated disease.
The hypothesis of a Botox-like neurotoxin is not tenable in this form.
The immunological bridge between the gut and the CNS, however, is becoming increasingly plausible based on the data.
Further relevant studies on this topic (gut bacteria, toxins/metabolites, MS, mouse models)
- Berer K et al. (2017) – Proc Natl Acad Sci USA. Transfer of MS patient microbiota to mice increases autoimmunity and incidence of encephalomyelitis. https://www.pnas.org/doi/10.1073/pnas.1615718114
- Linden JR et al. (2023 or earlier) – J Clin Invest. Epsilon-toxin–producing Clostridium perfringens strains in the MS gut microbiome; ETX crosses the blood–brain barrier and induces lesions in mouse models. https://www.jci.org/articles/view/163239
- Various reviews on FMT in neurodegeneration/MS (2023–2025). FMT from healthy donors alleviates motor deficits in MS-like models; conversely, MS microbiota worsen symptoms. Examples:
Google CENSORSHIP!
Google censors my homepage quite a bit, sometimes I am not even able to find my articles on Google. So please sign up for the newsletter and share it with friends or via Facebook and use the search function on my website. Follow me on Twitter, where I also announce important articles.
